PRESCRIPTION DRUG MONITORING PROGRAM TRAINING AND TECHNICAL ASSISTANCE CENTER
The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) at the Institute for Intergovernmental Research (IIR) provides a comprehensive array of services, support, resources, & strategies to PDMPs, federal partners and other stakeholders to further the efforts and effectiveness of PDMPs in combating the misuse and diversion of prescription drugs.
News & Events
-
DEA to Host 31st National Prescription Drug Take Back Day on Saturday, October 24th
Read More October 08, 2026October 07, 2026 - WASHINGTON, DC –The U.S. Drug Enforcement Administration, in collaboration with more than 4,300 law enforcement partners, will host the 31st National Prescription Drug Take Back Day on Saturday, October 24, from 10 a.m. to 2 p.m.
More than 4,400 collection sites will be set up across the country to dispose of unneeded, expired, and unused prescription medications. This is a simple step that prevents diversion, reduces the risk of accidental poisonings, and helps protect communities.
See the link below for the full DEA press release.
-
Drugs of Abuse: A Resource Guide, 2026 Edition
Read More September 28, 2026The Drug Enforcement Administration (DEA) released an updated publication, Drugs of Abuse: A Resource Guide, 2026 Edition. Drugs of Abuse delivers clear, scientific information about drugs in a factual, straightforward way. With the information in this guide, parents and caregivers can help their children make smart choices and avoid the consequences of drug abuse. This publication covers topics including the Controlled Substances Act and introduces drug classes including narcotics, stimulants, marijuana/cannabis, inhalants, steroids, and more. More information can be found at https://www.getsmartaboutdrugs.gov (opens in a new tab).
Download the Guide at https://www.getsmartaboutdrugs.gov/sites/default/files/2026-09/Drugs-Abuse-2026.pdf. (opens in a new tab)
-
LAPPA publishes Model Addressing Inhalant Use Act
Read More August 25, 2026The Legislative Analysis and Public Policy Association (LAPPA) is excited to announce publication of the Model Addressing Inhalant Use Act (opens in a new tab). The purpose of this legislation is to: (1) prohibit the sale of certain products containing inhalants to minors; (2) establish additional requirements for the sale of inhalants, including restrictions on advertising and the retail sale of nitrous oxide as well as packaging requirements; (3) establish criminal penalties related to inhalants; and (4) establish education, prevention, and treatment requirements. Regulating inhalants is complicated because many inhalants are common household substances, but doing so is growing increasingly critical as this availability and appearance of “safety” results in adolescents being the largest demographic that uses inhalants. This Model Act seeks to: (1) to implement measures to educate the public, particularly adolescents, on the dangers of inhalant use; and (2) prevent initiation into inhalant use by placing restrictions on purchasing certain products.
Our focus is to improve consistency among PDMPs, facilitate coordination between PDMPs and state and national stakeholders, increase PDMP efficiencies, measure performance and effectiveness, and promote best practices.
REQUEST PDMP TTA
Combat prescription misuse with RxCheck! Facilitate seamless data sharing among states, integrate with EHR systems, and join the nationwide PDMP movement. Developed with BJA support, RxCheck ensures secure data governance, empowering states to own and control their information.
LEARN MORE
